Engineered Micro-Pancreas
preclinicalRestore regulated insulin release in diabetic patients and reduce dependence on daily insulin therapy.
Stem cell-derived or islet beta-cell transplantation using a tissue-engineered extracellular-matrix scaffold, described as a decellularized porcine lung-derived micro-scaffold or micro-organ matrix, to support insulin-producing cells and vascularized graft integration.
Preclinical mouse efficacy data reported for extracellular matrix-guided endocrine micro-pancreata, with the company roadmap describing future Phase I, Phase II, and Phase III development milestones.
In NOD-SCID mice, endocrine micro-pancreata showed increased glucose-stimulated insulin secretion in vitro, sustained insulin production, graft vascularization, and improved glycemic control after transplantation. Subcutaneous delivery showed stronger glucose tolerance improvement than intraperitoneal delivery.